Serum irisin associates with breast cancer to spinal metastasis

摘要

The aim of this study was to determine whether the serum level of irisin can be a candidate to predict the spinal metastasis in patients with breast cancer . In a cross-sectional study , 148 patients were recruited. Of those, 53 (35.8%) had spinal metastasis . The baseline characteristics were compared by status of spinal metastasis . Multiple logistic regression analysis was used to determine whether the serum irisin can be a candidate for predicting breast cancer to spinal metastasis . The correlation coefficient analysis was used to confirm the correlation between the serum irisin and lipid metabolic parameters and body mass index (BMI), respectively. The serum irisin was higher in patients without spinal metastasis (7.60 ± 3.80). Multivariable analysis showed that the serum irisin was protective to the presence of spinal metastasis in patients with breast cancer after adjustments of age and BMI (odds ratio, 0.873; 95% confidence interval, 0.764–0.999). Furthermore, there was a positive correlation between the serum irisin and BMI ( r = 0.263). The patients with metabolisc syndrome (MetS) had a higher level in serum irisin . In addition, the higher numbers of MetS components were associated with higher serum irisin . Higher serum irisin can be a protective factor of spinal metastasis in patients with breast cancer . The BMI is positively associated with the serum level of irisin. Furthermore, patients with MetS tended to have a higher level of serum irisin .